China SXT Pharmaceuticals (NASDAQ:SXTC) Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.
The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy. China SXT’s research platform encompasses preclinical discovery, process development and clinical-stage programs, with therapeutic indications such as cancer supportive care, diabetes and other hormone-related conditions. In addition to its internal pipeline, China SXT Pharmaceuticals offers custom peptide manufacturing services under cGMP conditions, supporting both small biotech firms and large pharmaceutical corporations in advancing their own drug candidates.
Headquartered in Nanjing, China, the company operates research and manufacturing facilities equipped for peptide synthesis, analytical development and scale-up production. Its integrated approach—from early discovery through commercial production—facilitates streamlined development timelines and cost efficiencies. China SXT maintains collaborations with academic institutions and contract research organizations to bolster its R&D capabilities.
While its primary market remains mainland China, China SXT Pharmaceuticals continues to explore regulatory pathways and partnership opportunities to expand its global footprint. The company’s management team comprises experienced professionals in biopharmaceutical research, development and regulatory affairs, guiding China SXT’s efforts to bring innovative peptide therapies from laboratory to market.
